The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Mironov A.V.

NII SP im. N.V. Sklifosovskogo

Gusev L.L.

City clinical hospital named after N.I. Pirogov, Moscow, Russia

Lebedev I.S.

Pirogov Russian National Research Medical University, Moscow, Russia;
Municipal Clinical Hospital No. 1 named after N.I. Pirogov, Moscow, Russia

Moskalenko E.P.

Kafedra fakul'tetskoĭ khirurgii Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova;
Gorodskaia klinicheskaia bol'nitsa #1 im. N.I. Pirogova

Kirienko A.I.

Russian National Research Medical University nabbed after N.I. Pirogov, Moscow, Russia

Andriiashkin V.V.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Prevention of recurrent deep vein thrombosis with intermediate-doses of low-molecular-weight heparin

Authors:

Leont'ev S.G., Mironov A.V., Gusev L.L., Lebedev I.S., Moskalenko E.P., Kirienko A.I., Andriiashkin V.V.

More about the authors

Journal: Journal of Venous Disorders. 2013;7(2): 15‑20

Views: 1583

Downloaded: 22

Download PDF (RU)
Contact the author
Table of contents

PREVENTION OF RECURRENT DEEP VEIN THROMBOSIS WITH INTERMEDIATE-DOSES OF LOW-MOLECULAR-WEIGHT HEPARIN
PREVENTION OF RECURRENT DEEP VEIN THROMBOSIS WITH INTERMEDIATE-DOSES OF LOW-MOLECULAR-WEIGHT HEPARIN

To cite this article:

Leont'ev SG, Mironov AV, Gusev LL, Lebedev IS, Moskalenko EP, Kirienko AI, Andriiashkin VV. Prevention of recurrent deep vein thrombosis with intermediate-doses of low-molecular-weight heparin. Journal of Venous Disorders. 2013;7(2):15‑20. (In Russ.)

 
Подписка 2025-2 (Journal of Venous Disorders)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Effi­cacy and Safety of Different Anti­coagulation Regi­mens for Deep Vein Thro­mbosis in Real Clinical Practice. Journal of Venous Diso­rders. 2024;(2):89-99
Primary prevention of computer game addi­ction in students of educational institutions. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):97-103
Gender differences in mental and beha­vioural diso­rders as an impo­rtant stage of cardiovascular diseases prevention in young people. Russian Journal of Preventive Medi­cine. 2024;(3):66-71
Colo­rectal cancer: inci­dence, risk factors, and screening. Russian Journal of Preventive Medi­cine. 2024;(3):93-97
Possibilities of cardiometabolic diseases prevention in women with pregnancy adve­rse outcomes in medi­cal history. Russian Journal of Preventive Medi­cine. 2024;(3):98-103
To the issue of early diagnosis of mali­gnant skin neoplasms during medi­cal check-ups. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(2):161-167
Rela­pse of primary mediastinal B-cell lymphoma with isolated central nervous system invo­lvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Onco­logy. 2024;(2):39-45
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Topi­cal application of hypo­tensive drugs for the prevention of intraocular pressure elevation after intravitreal inje­ctions of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;(2-2):73-79
Pharmacological prevention of fibrosis in dacryosurgery. Russian Annals of Ophthalmology. 2024;(2-2):180-189

Aim. The objective of the present study was to estimate the effectiveness and safety of the prevention of a relapse of deep venous thrombosis in the lower extremities using intermediate doses of low molecular weight heparins (LMWH) in comparison with standard therapy with the use of vitamin K antagonists (VKA). Material and methods. This comparative prospective non-randomized study included 106 patients presenting with deep venous thrombosis (DVT). They were allocated to two groups. Those comprising the study group (n=56) were prescribed LMWH at intermediate doses while the patients of the control group (n=50) were given the standard prophylactic treatment with the use of VKA. The results of the treatment were evaluated within 1, 3, and 6 months from the onset of pharmacotherapy. Results. One (1.8%) patient of the study group developed a relapse of DVT within 1 month after the beginning of observation. One case (2%) of relapse of thromboembolic complications was documented in the control group; it required hospitalization of the patient. There were no cases of pulmonary embolism among the patients of either group. One (1.8%) case of post-prophylactic complication (an allergic reaction to the heparin preparation) was documented in the group of patients treated with intermediate doses of LMWH. Three (6%) patients of the control group experienced hemorrhagic complications (macrohematuria and spontaneous retroperitoneal hematoma). No such complications were recorded in the study group. The effectiveness of the prophylactic treatment was estimated based on the characteristics of the patients' quality of life. The questionnaire study failed to demonstrate statistical differences between the quality of life indices depending on the pharmacotherapeutic modalities employed in the present study. Conclusion. The effects of intermediate doses of LMWH and VKA are comparable in terms of clinical effectiveness even though the prescription of LMWH at intermediate doses should be regarded as a safer therapeutic modality. We believe that the main criterion for the choice of an anticoagulant for long-term prophylaxis should be the risk of development of hemorrhage.

Keywords:

deep vein thrombosis
recurrence
prevention
intermediate-dose
low-molecular-weight heparin
vitamin K antagonists
deep vein thrombosis
recurrence
prevention
intermediate-dose
low-molecular-weight heparin
vitamin K antagonists

Authors:

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Mironov A.V.

NII SP im. N.V. Sklifosovskogo

Gusev L.L.

City clinical hospital named after N.I. Pirogov, Moscow, Russia

Lebedev I.S.

Pirogov Russian National Research Medical University, Moscow, Russia;
Municipal Clinical Hospital No. 1 named after N.I. Pirogov, Moscow, Russia

Moskalenko E.P.

Kafedra fakul'tetskoĭ khirurgii Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova;
Gorodskaia klinicheskaia bol'nitsa #1 im. N.I. Pirogova

Kirienko A.I.

Russian National Research Medical University nabbed after N.I. Pirogov, Moscow, Russia

Andriiashkin V.V.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

List of references:

  1. Rossiyskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhneniy. [Russian clinical recommendations on diagnostics and prophylaxis of venous thromboembolic complications] Flebologiya 2010; 1: 2: 3-37.
  2. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., Ray J.G. Prevention of venous thromboembolism: the seventh ACCP conference on Antithrombotic and Thrombotic Therapy. Chest 2004; 126:338S-400S.
  3. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.). Chest 2008;133: 6: Suppl:454S-545S.
  4. Agnelli G., Prandoni P., Becattini C., Silingardi M., Taliani M.R., Miccio M. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
  5. Hirsh J. Drug Therapy: oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.
  6. Barkagan Z.S., Momot A.P., Taranenko I.A., Shoykhet Ya.N. Osnovy prolongirovannoy profilaktiki i terapii tromboemboliyantikoagulyantami nepryamogo deystviya (pokazaniya, podbordoz, laboratornyymonitoring). Metodicheskie ukazaniya. Barnaul 2002; 53. [Fundamentals of long-term prevention and therapy of thromboembolism with indirect anticoagulants (indications, dosing, laboratory monitoring). Guidelines. Barnaul 2002, 53]
  7. Le Gal G., Mottier D. New anticoagulants in the treatment of VTE. Semin Respir Crit Care Med 2012;33: 2:191-198.
  8. Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R., Wong T., Cook R., Solymoss S., Poon M.C., Raskob G. LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007;120: 1:72-82.
  9. Hull R.D., Pineo G.F., Mah A.F., Brant R.F. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000;96:449a.
  10. Pini M., Aiello S., Manotti C., Pattacini R., Quintavalla R., Poli T., Tagliaferri A., Dettori A.G. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-197.
  11. Das S.K., Cohen A.T., Edmondson R.A., Melissari E., Kakkar V.V. Low-molecularweight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-526.
  12. Agnelli G., Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombol 2008;25: 1:37-44.
  13. Romera A., Cairols M.A., Vila-Coll R., Martí X., Colomé E., Bonell A., Lapiedra O. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37: 3:349-356.
  14. Launois R., Reboul-Marty J., Henry B. Construction and validation of a Quality of Life questionnaire in chronic venous insufficiency of lower limbs. Qual Life Res 1996;5:539-554.
  15. Fihn S.D., McDonell M., Martin D., Henikoff J., Vermes D., Kent D., White R.H. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993;118: 7:511-520.
  16. Palareti G., Leali N., Coccheri S., Poggi M., Аnotti C., D'Angelo A. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428.
  17. Van der Heijden J.F., Hutten B.A., Buller H.R., Prins M.H. Vitamin K antagonist or low-molecular-weight heparin for the long-term treatment of venous thromboembolism. J Exp Clin Cancer Res 2008;21-27.
  18. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., Le Maignan C., Extra J.M., Cottu P., Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
  19. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., Rickles F.R., Julian J.A., Haley S., Kovacs M.J., Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
  20. Hull R., Hirsh J., Jay R., Carter C., England C. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
  21. Kearon C., Ginsberg J.S., Kovacs M.J., Anderson D.R., Wells P., Julian J.A., MacKinnon B., Weitz J.I., Crowther M.A., Dolan S., Turpie A.G., Geerts W., Solymoss S., van Nguyen P., Demers C., Kahn S.R., Kassis J., Rodger M., Hambleton J., Gent M.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639.
  22. Beckman J.A., Dunn K., Sasahara A.A., Goldhaber S.Z. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003;89:953-958.
  23. Hamann H. Secondary prevention after deep venous thrombosis: low molecular weight heparin versus coumarin. Zentral Chir 1999;124:24-26.
  24. Veiga F., Escriba A., Maluenda M.P., López Rubio M., Margalet I., Lezana A., Gallego J., Ribera J.M. Low-molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84:559-564.
  25. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., Pengo V., Erba N., Moia M., Ciavarella N., Devoto G., Berrettini M., Musolesi S. On behalf of the Italian Study on Complications of Oral Anticoagulant Therapy/Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.